Dermira: Evommune In-Licenses Three Development Programs Focused on Treating Inflammatory Conditions from Dermira, a Wholly-Owned Subsidiary of Eli Lilly and Company

Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced it has entered into an exclusive license agreement with Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, to develop and commercialize three development programs for the treatment of various inflammatory disea